Search Results
Search for other papers by Philippe L Bedard in
Google Scholar
PubMed
Search for other papers by Sandeep K Singhal in
Google Scholar
PubMed
Search for other papers by Michail Ignatiadis in
Google Scholar
PubMed
Division of Medical Oncology and Hematology, Breast Cancer Translational Research Laboratory JC Heuson, Frontier Science (Scotland) Ltd, School of Medicine, Machine Learning Group, Novartis Institutes for BioMedical Research, Breakthrough Breast Research Group, University of Edinburgh, Department of Biostatistics and Computational Biology, Department of Medicine, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
Search for other papers by Ian Bradbury in
Google Scholar
PubMed
Division of Medical Oncology and Hematology, Breast Cancer Translational Research Laboratory JC Heuson, Frontier Science (Scotland) Ltd, School of Medicine, Machine Learning Group, Novartis Institutes for BioMedical Research, Breakthrough Breast Research Group, University of Edinburgh, Department of Biostatistics and Computational Biology, Department of Medicine, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
Division of Medical Oncology and Hematology, Breast Cancer Translational Research Laboratory JC Heuson, Frontier Science (Scotland) Ltd, School of Medicine, Machine Learning Group, Novartis Institutes for BioMedical Research, Breakthrough Breast Research Group, University of Edinburgh, Department of Biostatistics and Computational Biology, Department of Medicine, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
Search for other papers by Benjamin Haibe-Kains in
Google Scholar
PubMed
Search for other papers by Christine Desmedt in
Google Scholar
PubMed
Search for other papers by Sherene Loi in
Google Scholar
PubMed
Search for other papers by Dean B Evans in
Google Scholar
PubMed
Search for other papers by Stefan Michiels in
Google Scholar
PubMed
Search for other papers by J Michael Dixon in
Google Scholar
PubMed
Search for other papers by William R Miller in
Google Scholar
PubMed
Search for other papers by Martine J Piccart in
Google Scholar
PubMed
Search for other papers by Christos Sotiriou in
Google Scholar
PubMed
genomic grade and high genomic grade tumors, with long-term outcomes that resemble low and high histological grade tumors in the absence of systemic therapy ( Sotiriou et al . 2006 ). At least, four distinct clinically relevant molecular subtypes of
Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Florian Bösch in
Google Scholar
PubMed
Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Katharina Brüwer in
Google Scholar
PubMed
Search for other papers by Annelore Altendorf-Hofmann in
Google Scholar
PubMed
Department of Internal Medicine 4, Ludwig-Maximilians-University Munich, Munich, Germany
Search for other papers by Christoph J Auernhammer in
Google Scholar
PubMed
Department of Internal Medicine 4, Ludwig-Maximilians-University Munich, Munich, Germany
Search for other papers by Christine Spitzweg in
Google Scholar
PubMed
Department of Medicine 3 and Comprehensive Cancer Center, Ludwig-Maximilians-University Munich, Munich, Germany
Search for other papers by C Benedikt Westphalen in
Google Scholar
PubMed
Department of Medicine 3 and Comprehensive Cancer Center, Ludwig-Maximilians-University Munich, Munich, Germany
Search for other papers by Stefan Boeck in
Google Scholar
PubMed
Munich Cancer Registry (MCR) of the Munich Tumour Centre (TZM), Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), Ludwig-Maximilians-University Munich, Munich, Germany
Search for other papers by Gabriele Schubert-Fritschle in
Google Scholar
PubMed
Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Jens Werner in
Google Scholar
PubMed
Department of Medicine 3 and Comprehensive Cancer Center, Ludwig-Maximilians-University Munich, Munich, Germany
Search for other papers by Volker Heinemann in
Google Scholar
PubMed
Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany
Search for other papers by Thomas Kirchner in
Google Scholar
PubMed
Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Martin Angele in
Google Scholar
PubMed
Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany
Search for other papers by Thomas Knösel in
Google Scholar
PubMed
1.6 Correlation between TILs, PD-1 and PD-L1 expression and grading High TILs (≥3 lymphocytes per TMA-spot) could be evaluated in 47 cases (19.6%). High PD-1 expression in TILs was seen in 35 samples (16.1%), and 20 samples (8
Search for other papers by Cindy H Chau in
Google Scholar
PubMed
Search for other papers by Cathee Till in
Google Scholar
PubMed
Search for other papers by Douglas K Price in
Google Scholar
PubMed
Search for other papers by Phyllis J Goodman in
Google Scholar
PubMed
Search for other papers by Marian L Neuhouser in
Google Scholar
PubMed
Search for other papers by Michael N Pollak in
Google Scholar
PubMed
Search for other papers by Ian M Thompson in
Google Scholar
PubMed
Search for other papers by William D Figg in
Google Scholar
PubMed
data from the Prostate Cancer Prevention Trial (PCPT), we previously found obesity is associated with an increased risk of high-grade prostate cancer and a decreased risk of low-grade disease ( Gong et al. 2006 ). In the current follow-up study, we
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
Crown Princess Mary Cancer Centre, Westmead Hospital, Western Sydney Local Health District, New South Wales, Australia
Blacktown Cancer and Haematology Centre, Blacktown Hospital, Western Sydney Local Health District, New South Wales, Australia
Search for other papers by Tania Moujaber in
Google Scholar
PubMed
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
Children’s Medical Research Institute, Sydney, New South Wales, Australia
Search for other papers by Rosemary L Balleine in
Google Scholar
PubMed
Crown Princess Mary Cancer Centre, Westmead Hospital, Western Sydney Local Health District, New South Wales, Australia
Blacktown Cancer and Haematology Centre, Blacktown Hospital, Western Sydney Local Health District, New South Wales, Australia
Search for other papers by Bo Gao in
Google Scholar
PubMed
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
Department of Gynaecological Oncology, Westmead Hospital, Western Sydney Local Health District, New South Wales, Australia
Search for other papers by Ida Madsen in
Google Scholar
PubMed
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
Crown Princess Mary Cancer Centre, Westmead Hospital, Western Sydney Local Health District, New South Wales, Australia
Search for other papers by Paul R Harnett in
Google Scholar
PubMed
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
Department of Gynaecological Oncology, Westmead Hospital, Western Sydney Local Health District, New South Wales, Australia
The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council New South Wales, Sydney, New South Wales, Australia
Search for other papers by Anna DeFazio in
Google Scholar
PubMed
recent molecular characterisation that LGSC has been fully designated as distinct from high-grade serous cancer (HGSC), with different pathogenesis, treatment response and clinical course. The benefit of this revised classification has been an
Department of Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden
Search for other papers by C Christofer Juhlin in
Google Scholar
PubMed
Endocrine Oncology Site, Princess Margaret Cancer Centre, Toronto, ON, Canada
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
Search for other papers by Ozgur Mete in
Google Scholar
PubMed
Search for other papers by Zubair W Baloch in
Google Scholar
PubMed
, completely follicular-patterned with PTC-related nuclear atypia lacking high-grade features (mitoses/necrosis) ( Hodak et al. 2016 , Thompson 2016 ). Most NIFTPs are RAS -driven or exhibit codon 601 BRAF mutations, and presence of BRAF p. V600E
Search for other papers by Larissa Akemi Kido in
Google Scholar
PubMed
Search for other papers by Fabio Montico in
Google Scholar
PubMed
Search for other papers by Rafael Sauce in
Google Scholar
PubMed
Search for other papers by Aline Barbosa Macedo in
Google Scholar
PubMed
Search for other papers by Elaine Minatel in
Google Scholar
PubMed
Department of Organic Chemistry, Institute of Chemistry, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil
Search for other papers by Débora Barbosa Vendramini Costa in
Google Scholar
PubMed
Faculty of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil
Search for other papers by João Ernesto de Carvalho in
Google Scholar
PubMed
Search for other papers by Ronaldo Aloise Pilli in
Google Scholar
PubMed
Search for other papers by Valeria Helena Alves Cagnon in
Google Scholar
PubMed
following specifications: (1) normal tissue (NT); (2) low-grade prostatic intraepithelial neoplasia (LGPIN); (3) high-grade prostatic intraepithelial neoplasia (HGPIN); (4) well-differentiated adenocarcinoma; and (5) undifferentiated adenocarcinoma ( Fig. 1A
Search for other papers by M Cives in
Google Scholar
PubMed
Search for other papers by P L Kunz in
Google Scholar
PubMed
Search for other papers by B Morse in
Google Scholar
PubMed
Search for other papers by D Coppola in
Google Scholar
PubMed
Search for other papers by M J Schell in
Google Scholar
PubMed
Search for other papers by T Campos in
Google Scholar
PubMed
Search for other papers by P T Nguyen in
Google Scholar
PubMed
Search for other papers by P Nandoskar in
Google Scholar
PubMed
Search for other papers by V Khandelwal in
Google Scholar
PubMed
Search for other papers by J R Strosberg in
Google Scholar
PubMed
have locally unresectable or metastatic grade 1 or 2 pancreatic or extra-pancreatic NETs. Mitotic count and ki-67 thresholds for the tumor grade index were based on the World Health Organization (WHO) 2010 classification ( Rindi & Arnold 2010
Search for other papers by J R Strosberg in
Google Scholar
PubMed
Search for other papers by M Cives in
Google Scholar
PubMed
Search for other papers by J Hwang in
Google Scholar
PubMed
Search for other papers by T Weber in
Google Scholar
PubMed
Search for other papers by M Nickerson in
Google Scholar
PubMed
Search for other papers by C E Atreya in
Google Scholar
PubMed
Search for other papers by A Venook in
Google Scholar
PubMed
Search for other papers by R K Kelley in
Google Scholar
PubMed
Search for other papers by T Valone in
Google Scholar
PubMed
Search for other papers by B Morse in
Google Scholar
PubMed
Search for other papers by D Coppola in
Google Scholar
PubMed
Search for other papers by E K Bergsland in
Google Scholar
PubMed
classification ( Rindi & Arnold 2010 ). Patients with poorly differentiated or high-grade tumors were excluded. Patients were required to have evidence of progressive disease within 12months of study entry. Any number of prior systemic or locoregional treatments
Search for other papers by Catherine T Choy in
Google Scholar
PubMed
Search for other papers by Haseong Kim in
Google Scholar
PubMed
Search for other papers by Ji-Young Lee in
Google Scholar
PubMed
Search for other papers by David M Williams in
Google Scholar
PubMed
Search for other papers by David Palethorpe in
Google Scholar
PubMed
Search for other papers by Greg Fellows in
Google Scholar
PubMed
Search for other papers by Alan J Wright in
Google Scholar
PubMed
Search for other papers by Ken Laing in
Google Scholar
PubMed
Search for other papers by Leslie R Bridges in
Google Scholar
PubMed
Search for other papers by Franklyn A Howe in
Google Scholar
PubMed
Search for other papers by Soo-Hyun Kim in
Google Scholar
PubMed
that KAL1 was differentially expressed according to the grade and type of tumor, showing an upregulation in high-grade primary brain tumors. We also found that anosmin-1 enhanced proliferation and motility of glioblastoma cells in vitro , formed a
Search for other papers by Nicole Panarelli in
Google Scholar
PubMed
Search for other papers by Kathrin Tyryshkin in
Google Scholar
PubMed
Search for other papers by Justin Jong Mun Wong in
Google Scholar
PubMed
Search for other papers by Adrianna Majewski in
Google Scholar
PubMed
Search for other papers by Xiaojing Yang in
Google Scholar
PubMed
Search for other papers by Theresa Scognamiglio in
Google Scholar
PubMed
Search for other papers by Michelle Kang Kim in
Google Scholar
PubMed
Search for other papers by Kimberly Bogardus in
Google Scholar
PubMed
Search for other papers by Thomas Tuschl in
Google Scholar
PubMed
Search for other papers by Yao-Tseng Chen in
Google Scholar
PubMed
HHMI, Laboratory of RNA Molecular Biology, The Rockefeller University, New York, New York, USA
Search for other papers by Neil Renwick in
Google Scholar
PubMed
improve as more samples are sequenced. Whether miR-328 would be a useful adjunct marker for assessing high-grade pancreatic NETs or for grading NETs in other anatomic sites is being explored. Direct comparison of our miRNA expression data with those